R&D | December 22, 2025
Xeureka & UBE launch joint cancer drug discovery program
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Subscribe To Our Newsletter & Stay Updated
